Thomas Dumortier
Novartis
21 Papers
90 Citations
Thomas Dumortier is an academic researcher from Novartis. The author has contributed to research in topics: Losartan & Regimen. The author has an hindex of 9, co-authored 21 publications. Previous affiliations of Thomas Dumortier include Merck & Co..
Chat about Author
Papers
Two-year effects of alendronate on bone mineral density and vertebral fracture in patients receiving glucocorticoids: a randomized, double-blind, placebo-controlled extension trial.
Jonathan D. Adachi,Kenneth G. Saag,Pierre D. Delmas,Uri A. Liberman,Ronald Emkey,Ego Seeman,Nancy E Lane,Jean-Marc Kaufman,Patrice E. Poubelle,Federico Hawkins,Ricardo Correa-Rotter,Charles J. Menkes,Jose Adolfo Rodriguez-Portales,Thomas J. Schnitzer,Joel A. Block,Jeffrey Wing,Harris H. McIlwain,Rene Westhovens,Jacques P. Brown,J Melo-Gomes,Barry L. Gruber,Melissa J. Yanover,M O R Leite,Kerry Siminoski,Michael C. Nevitt,John T. Sharp,Marie Pierre Malice,Thomas Dumortier,Michelle Czachur,Wendy L. Carofano,Daifotis Anastasia G +30 more
TL;DR: Alendronate is an effective, well-tolerated therapy for the prevention and treatment of glucocorticoid-induced osteoporosis, with sustained treatment advantages for up to 2 years.
572
Safety, tolerability, and antibody response of active Aβ immunotherapy with CAD106 in patients with Alzheimer's disease: randomised, double-blind, placebo-controlled, first-in-human study
Bengt Winblad,Niels Andreasen,Lennart Minthon,Annette Floesser,Georges Imbert,Thomas Dumortier,R. Paul Maguire,Kaj Blennow,Joens Lundmark,Matthias Staufenbiel,Jean-Marc Orgogozo,Ana Graf +11 more
TL;DR: The findings suggest that CAD106 has a favourable safety profile and acceptable antibody response in patients with Alzheimer's disease.
313
The PKC inhibitor AEB071 may be a therapeutic option for psoriasis
Hans Skvara,Markus Dawid,Elise Kleyn,Barbara Wolff,Josef G. Meingassner,Hilary Knight,Thomas Dumortier,Tamara Kopp,Nasanin Fallahi,Georg Stary,Christoph Burkhart,Olivier Grenet,Juergen Wagner,Youssef Hijazi,Randall E. Morris,Claire McGeown,Christiane Rordorf,Christopher E.M. Griffiths,Georg Stingl,Thomas Jung +19 more
TL;DR: It is shown that the PKC inhibitor AEB071 both abolishes the production of several cytokines by activated human T cells, keratinocytes, and macrophages in vitro and inhibits an acute allergic contact dermatitis response in rats, and that AEB 071 warrants long-term studies to establish safety and efficacy.
167
•Journal Article
Increased efficacy and tolerability with losartan plus hydrochlorothiazide in patients with uncontrolled hypertension and therapy-related symptoms receiving two monotherapies.
D. P. Naidoo,P. Sareli,F. Marin,G. Aroca-Martinez,F. J. Maritz,P. C. B. V. Jardim,A. A. Guerrero,C. A. Thompson,T. Bero,J. Drazka,V. Kosmalova,Thomas Dumortier,Ronald D. Smith +12 more
TL;DR: The combination of losartan 100 mg/HCTZ 25 mg offers a beneficial therapeutic option for patients with a history of moderate to severe hypertension whose blood pressure is not adequately controlled or who exhibit side effects while on two or more single-agent antihypertensive drugs.
23